BLRX - BioLineRx Ltd

https://www.biolinerx.com

Recent News

Why BioLineRx Shares Are Getting Obliterated Monday - BioLine Rx ( NASDAQ:BLRX )

BioLine RX Ltd - ADR BLRX shares are trading lower by 32.21% to $1.06 Monday morning after the company announced a $15 million registered direct offering. The offering is expected to close on or about September 21st, subject to satisfaction of customary closing conditions.

Neutral

Recap: BioLine Rx Q1 Earnings

Benzinga • 3 years, 4 months ago • score: 0.00

BioLine Rx ( NASDAQ:BLRX ) reported its Q1 earnings results on Wednesday, May 11, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings BioLine Rx beat estimated earnings by 33.33%, reporting ...Full story available on Benzinga.com

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company is headquartered in Hevel Modi'in, Israel.

52W High

$26.80

52W Low

$2.30

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.89

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

93.46

EV/EBITDA (<8 favorable)

0.22

EV/Revenue (<3 favorable)

0.02

P/S (TTM) (<3 favorable)

0.93

P/B (<3 favorable)

0.78

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

4.08%

Institutions (25–75% balanced)

1.55%

Shares Outstanding

4,262,700

Float

2,450,908,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

17,251,000

Gross Profit (TTM)

10,234,000

EPS (TTM)

-6.00

Profit Margin (>10% good)

-0.45%

Operating Margin (TTM) (higher better)

-7.58%

ROE (TTM) (>15% strong)

-0.46%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.94

Momentum

Value

N/A

Trend

—

Signal Cross

No cross

As of

—